Fibronostics

The best liver assessment solutions don't require laboratories to change how they work. For widespread adoption, noninvasive liver assessment must fit seamlessly into existing laboratory workflows—not require new infrastructure or specialised equipment. LIVERFASt™ was designed for routine implementation using 10 commonly available blood biomarkers, supporting: • Automated laboratory workflows • Integration into existing laboratory information systems (LIS) • Scalable deployment across clinics, hospitals, and reference laboratories • High-throughput testing using routine blood samples Because innovation should integrate into clinical practice—not complicate it. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/m719z #LaboratoryMedicine #ClinicalLaboratories #MASLD #MASH #LIVERFASt #LaboratoryWorkflow #ClinicalInnovation #Fibronostics

Did you know not all non-invasive liver assessment tools provide the same level of clinical clarity? Many commonly used scores, including FIB-4, can leave a significant proportion of patients in an indeterminate "grey zone," making it more difficult to determine the most appropriate next step. LIVERFASt™ was designed to help reduce this uncertainty by providing biopsy-aligned assessment of fibrosis (F0–F4), steatosis (S0–S3), and inflammatory activity (A0–A3) from a single routine blood sample. Because better clinical decisions begin with clearer clinical insights. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/zeRq8 #DidYouKnow #ClinicalPathways #MASLD #MASH #LIVERFASt #LiverHealth #ClinicalDecisionMaking #Fibronostics

Every patient's journey is different. Clinical decisions shouldn't rely on assumptions. Patients with MASLD progress at different rates, and no two clinical pathways are exactly alike. From identifying patients at increased risk to further evaluation, management, and longitudinal monitoring, each step depends on having meaningful clinical information at the right time. LIVERFASt™ provides biopsy-aligned assessment of fibrosis, steatosis, and inflammatory activity, helping clinicians better understand disease severity and support informed patient management. Because every clinical decision shapes the next step in a patient's journey. Learn more about the clinical evidence behind LIVERFASt™: https://lnkd.in/g52CHnaV #ClinicalPathways #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #LiverHealth #RiskStratification #Fibronostics

What should happen after identifying a patient at increased risk of advanced fibrosis? Identifying the right patient is only the first step.The real value of liver assessment lies in what happens next. Should the patient be referred for specialist evaluation? Would additional assessment provide greater clinical clarity? Should follow-up be scheduled sooner? Or is longitudinal monitoring the most appropriate course? LIVERFASt™ was designed to support these clinical decisions by providing biopsy-aligned fibrosis staging, together with steatosis and activity assessment, helping clinicians better understand where a patient sits on the disease spectrum and what action may be appropriate next. Because a test result should do more than report a finding. It should help guide patient management. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/rd5Wt #ClinicalPathways #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #RiskStratification #LiverHealth #ClinicalEvidence #Fibronostics

A liver assessment is only valuable if it helps answer one question: What should I do next? For clinicians managing patients with MASLD/MASH, every assessment has the potential to influence the next step in care, whether that means: • Referring a patient for specialist evaluation • Prioritising further diagnostic assessment • Initiating or intensifying lifestyle interventions • Monitoring disease progression over time • Identifying patients who may benefit from emerging therapies LIVERFASt™ was designed to support these everyday clinical decisions by providing biopsy-aligned fibrosis staging, along with steatosis and activity assessment, helping translate laboratory data into clinically meaningful insights. Because clinicians don't just need results. They need information that supports confident decisions and better patient care. Learn more about the clinical evidence behind LIVERFASt™: https://zurl.co/TXJaY #PhysicianPerspective #ClinicalDecisionMaking #MASLD #MASH #LIVERFASt #ClinicalPathways #RiskStratification #LiverHealth #ClinicalEvidence #Fibronostics

Did you know? Liver fibrosis can progress silently for years before symptoms appear. Many patients feel well even as liver scarring advances, meaning clinically significant fibrosis may already be present by the time symptoms develop. That's why waiting for symptoms is not an effective strategy. Earlier identification begins with assessing patients who are at increased metabolic risk, before liver disease progresses unnoticed. Published studies have demonstrated that LIVERFASt™ delivers higher sensitivity and higher negative predictive value (NPV) than FIB-4 for identifying advanced fibrosis in patients with MASLD, helping clinicians identify more at-risk patients who may benefit from further evaluation. Because the earlier fibrosis is identified, the greater the opportunity to support timely intervention, informed clinical decisions, and better patient management. Explore the clinical evidence behind LIVERFASt™: https://zurl.co/UKyH4 #DidYouKnow #Fibrosis #MASLD #EarlyDetection #LIVERFASt #ClinicalEvidence #RiskStratification #LiverHealth #ClinicalResearch #Fibronostics

Simple for laboratories. Powerful for clinicians. Adopting new liver assessment technology shouldn't require laboratories to reinvent their workflow. LIVERFASt™ was designed to fit seamlessly into routine laboratory operations, making implementation practical without adding unnecessary complexity. With LIVERFASt™, laboratories can: • Use a single routine blood sample • Analyze 10 commonly available biomarkers • Leverage existing laboratory infrastructure • Scale testing efficiently across low- or high-volume workflows • Deliver clinically meaningful fibrosis, steatosis, and activity insights within days Simple laboratory integration helps make advanced liver assessment more accessible to the clinicians and patients who need it. Because innovation is most valuable when it fits into everyday clinical practice. Learn more about LIVERFASt™: https://zurl.co/LXQaH #LIVERFASt #LaboratoryWorkflow #ClinicalLaboratory #MASLD #MASH #LiverHealth #HealthcareInnovation #ClinicalPathways #NonInvasiveAssessment #Fibronostics

Fibrosis is the build-up of scar tissue in the liver, usually caused by ongoing inflammation and injury. It progresses along a spectrum, from F0, indicating no fibrosis, to F4, indicating cirrhosis. The challenge is that fibrosis can advance silently, while patients may continue to feel well. This is why accurate staging matters. LIVERFASt™ provides biopsy-aligned fibrosis staging across the familiar F0 to F4 framework, helping clinicians understand where a patient sits on the fibrosis spectrum and what action may be appropriate next. Earlier identification can support more informed follow-up, referral, treatment consideration, and monitoring. Because fibrosis is not just a score, It is a stage that can help guide patient care. #UnderstandingLiverHealth #Fibrosis #MASLD #LIVERFASt #LiverHealth #RiskStratification #ClinicalDecisionMaking #Fibronostics

Metabolic disease. Liver disease. The same patient. MASLD is more than a liver condition. It is closely associated with metabolic dysfunction, including type 2 diabetes (T2DM), obesity, hypertension, and dyslipidaemia, placing millions of patients at increased risk of progressive liver fibrosis. Yet liver involvement often remains clinically silent until more advanced disease has developed. Understanding the relationship between metabolic health and liver health is only the first step. The next step is identifying patients who may benefit from further assessment before opportunities for earlier intervention are missed. Designed specifically for patients with MASLD/MASH, LIVERFASt™ provides blood-based assessment of fibrosis, steatosis, and activity, helping clinicians support earlier identification, meaningful risk stratification, and more informed patient management. Because treating metabolic disease also means understanding liver health. Explore the growing clinical evidence behind LIVERFASt™: https://zurl.co/Cl4Tt #MASLD #MetabolicHealth #Type2Diabetes #T2D #LIVERFASt #LiverHealth #Fibrosis #Steatosis #RiskStratification #ClinicalEvidence #HealthcareInnovation #Fibronostics

Patients with type 2 diabetes (T2DM) are among the highest-risk populations for developing advanced liver fibrosis. The challenge is that liver disease in these patients often progresses silently, with many remaining undiagnosed until fibrosis has reached a more advanced stage. Traditional assessment approaches may not identify every patient who could benefit from further evaluation. Published studies have demonstrated that LIVERFASt™ delivers higher sensitivity and higher negative predictive value (NPV) than FIB-4 for identifying advanced fibrosis in patients with MASLD, including those with T2D, helping identify more at-risk patients earlier. Because earlier identification creates opportunities for earlier intervention, more informed clinical decisions, and better patient management. Learn more about the growing clinical evidence behind LIVERFASt™: https://zurl.co/HDO6g #DidYouKnow #Type2Diabetes #T2D #MASLD #LIVERFASt #Fibrosis #EarlyDetection #ClinicalEvidence #RiskStratification #LiverHealth #ClinicalResearch #Fibronostics